       Document 0509
 DOCN  M9590509
 TI    Pretreatment with beta-funaltrexamine blocks morphine-mediated
       suppression of CTL activity in alloimmunized mice.
 DT    9509
 AU    Carpenter GW; Carr DJ; Department of Microbiology, Immunology and
       Parasitology, LSU; Medical Center, New Orleans 70112-1393, USA.
 SO    Immunopharmacology. 1995 Mar;29(2):129-40. Unique Identifier : AIDSLINE
       MED/95293637
 AB    The effect of prolonged exposure to morphine on cytotoxic T lymphocytes
       (CTL) and splenic natural killer (NK) activity was investigated. Daily
       administration of morphine (50.0 mg/kg, s.c.) to alloimmunized mice for
       11 days resulted in a significant decrease (25-50%) in peritoneal and
       splenic CTL activity but not splenic NK activity. To identify the
       effector cell population mediating cytolysis, cell enrichment studies
       were carried out. The results of these studies indicated the CTLs are
       CD8+ CD4-. Chronic morphine treatment increased the percentage (25-30%)
       of CD3+ CD4+ and CD8+, but not Ig+ cells in the spleen relative to
       saline-treated controls. Pretreatment of mice with the mu-selective
       antagonist, beta-funaltrexamine blocked morphine-mediated suppression of
       splenic and peritoneal CTL activity as well as the increase in CD3+ CD4+
       and CD8+ splenic lymphocytes. These results indicate the generation of
       CTLs in vivo is sensitive to chronic morphine exposure implicating
       opiates as important co-factors through modulation of cell-mediated
       immunity.
 DE    Animal  CD4-Positive T-Lymphocytes/DRUG EFFECTS/IMMUNOLOGY  CD8-Positive
       T-Lymphocytes/DRUG EFFECTS/IMMUNOLOGY  Female  Immunization  In Vitro
       Isoantigens  Killer Cells, Natural/DRUG EFFECTS/IMMUNOLOGY  Lymphocyte
       Transformation/DRUG EFFECTS  Mice  Mice, Inbred C3H  Mice, Inbred C57BL
       Morphine/*ANTAGONISTS & INHIB/*PHARMACOLOGY  Naltrexone/*ANALOGS &
       DERIVATIVES/PHARMACOLOGY  Spleen/DRUG EFFECTS/IMMUNOLOGY  Support,
       Non-U.S. Gov't  Support, U.S. Gov't, Non-P.H.S.  T-Lymphocytes,
       Cytotoxic/*DRUG EFFECTS/IMMUNOLOGY  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).

